📰 Solid Tumors News
Page 46 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
May 16, 2022
– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022... | May 16, 2022
May 13, 2022
MILAN, Italy and NEW YORK, May 13, 2022 -- Genenta Science , a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer,...
May 11, 2022
 Granted FDA Fast Track Designation for Lead APC Clinical CandidateReceived FDA IND Clearance to Initiate Phase 1/2 Clinical Trial of Next Generation eAPC Therapeutic Candidate for HPV16+ Solid TumorsPublished Peer Reviewed, Comprehensive Preclinical Research Supporting SQZ® APC and TAC Therapeutic ProgramsAnticipat...
May 11, 2022
AUM Biosciences partners with Roche for development of AUM001 in combination with anti-PD-L1 therapy in solid tumor indications
May 10, 2022
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H 2022 with target 10,000 doses/yrBCMA-CAR-iNKT and stromal-CAR-iNKT... | May 10, 2022
May 5, 2022
Editas Medicine Announces First Quarter 2022 Results and Business Updates - read this article along with other careers information, tips and advice on BioSpace
May 2, 2022
/PRNewswire/ -- LUMICKS, a leading life science tools company developing instruments and consumables for dynamic single-molecule and cell avidity analysis,...
April 29, 2022
NEW ORLEANS: A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in...
April 28, 2022
The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of
April 27, 2022
27.04.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the ... Seite 1